ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 26, 2022 at 12:57 am
Share
ChengDu ShengNuo Biotec Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 80.74 million compared to CNY 93.28 million a year ago. Revenue was CNY 80.74 million compared to CNY 93.28 million a year ago. Net income was CNY 14.29 million compared to CNY 11.65 million a year ago. Basic earnings per share from continuing operations was CNY 0.18 compared to CNY 0.19 a year ago. Diluted earnings per share from continuing operations was CNY 0.18 compared to CNY 0.19 a year ago.
ChengDu Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's main business includes independent research and development, production and sales of peptide APIs and preparations, providing pharmaceutical research services for peptide innovative drugs, customized production services for peptide products and transfer services for peptide drug production technology for domestic and foreign pharmaceutical companies, providing original equipment manufacture processing of small molecule chemical drug levosimendan preparations and levosimendan API production, export and sales business. The Company's products target areas including immunity, digestive tract, antiviral, obstetrics and gynecology, diabetes, cardiovascular and cerebrovascular, rare diseases, orthopedics and others. The Company mainly conducts its business in domestic and foreign markets.